New combo pill targets two heart risks at once

NCT ID NCT06165250

Completed Disease control Sponsor: Boryung Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tested whether taking two experimental drugs, BR1018B and BR1018C, together can safely lower both blood pressure and LDL cholesterol. The study involved 156 adults with essential hypertension and primary hypercholesterolemia. Participants were randomly assigned to different drug combinations to compare effectiveness over 8 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BR1018B and BR1018C (drugs for blood pressure and cholesterol)
What this could lead to: If successful, this could offer a new combination treatment option for people with both high blood pressure and high cholesterol.
What could go wrong: This is a completed Phase 3 trial, but results are not yet published. It may not show a meaningful advantage over existing treatments, and individual responses can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESSENTIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESSENTIAL HYPERTENSION PRIMARY HYPERCHOLESTEROLEMIA

Contacts and locations

Locations

Keimyung University Dongsan Hospital

Daegu, South Korea
Seoul National University Boramae Medical Center

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.